Description: Phylogica Limited is engaged in the provision of peptide discovery services to the pharmaceutical industries. The Company's principal activity is drug discovery research and development, whether in its own right or in partnership with international pharmaceutical companies, utilizing the Company's Phylomer peptide libraries and screening capabilities. It operates through the segment of discovery and development of therapeutics. The Company's Phylomer libraries contain an array of natural peptides, known as Phylomer peptides that represent a class of biological therapeutics. Phylomer peptides act as high affinity peptide disruptors of protein-protein interactions and binders of protein targets. The Phylomer libraries are based on expressed sequences of protein fragments that are encoded by the natural genes of evolutionary diverse microbes. Phylomer peptides consist of 15 to 50 amino acids. Dynamic Microbials Limited is a subsidiary of the Company.
Home Page: pyctx.com
PYC Technical Analysis
Harry Perkins Institute of Med Research
Nedlands,
WA
6009
Australia
Phone:
61 8 6151 0992
Officers
| Name | Title |
|---|---|
| Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.) | CEO & Exec. Director |
| Mr. Andrew Taylor B.Com., C.A. | Chief Financial Officer |
| Prof. Sue Fletcher | Chief Scientific Officer |
| Dr. May Orfali M.B.A., M.D. | Chief Medical Officer of US Operations |
| Dr. Glenn Noronha | Chief Devel. Officer |
| Mr. Kevin Ronald Hart B.Com, B.Comm (Hons), C.A., F.C.A., FCA | Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.2541 |
| Price-to-Sales TTM: | 12.6898 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |